DENTSPLY SIRONA Inc

DENTSPLY SIRONA Inc operates with a debt-to-equity ratio of 1.74, indicating a relatively high leverage position compared to industry norms. The company's liquidity is assessed as medium, with a current ratio of 1.51, suggesting it can cover its short-term obligations but with limited buffer. The company's price-to-book ratio of 1.49 implies that the market values the company at a premium to its book value, while the tangible book value is similarly valued. Profitability metrics show a challenging performance, with a return on equity of -0.4466 and a return on assets of -0.1101, both significantly below the industry median. The company reported a net loss of $598 million, with an operating loss of $422 million, indicating operational inefficiencies or cost overruns. Gross profit of $1.84 billion represents 50% of revenue, which is in line with industry norms but insufficient to cover operating expenses. The company's revenue is primarily concentrated in the dental equipment and consumables segments, with a global geographic footprint. However, the financial data does not provide a breakdown of revenue by segment or region, making it difficult to assess specific areas of strength or weakness. The company's exposure to international markets may introduce currency and regulatory risks. Looking ahead, the company is expected to face continued challenges, with a negative operating cash flow of $235 million and a free cash flow deficit of $505 million. Capital expenditures of $131 million suggest ongoing investment in infrastructure, but the lack of positive cash flow may constrain future growth. Analysts have a mixed outlook, with a mean price target of $13.96 and a median of $13.75, indicating some optimism despite the current financial performance. The company's risk profile includes liquidity concerns, with net cash being negative after subtracting total debt. The risk of dilution is assessed as low, but the company's financial position may necessitate additional financing in the future. The risk assessment highlights the need for improved operational efficiency and cost management to restore profitability. Recent events include the publication of the latest financial results, which show a significant net loss and operating loss. The company has not disclosed any major strategic changes or new product launches in the recent filings. The analyst community has issued a range of price targets, with a mean recommendation of 2.88, indicating a cautious outlook.